Merck Loses Final Bellwether Trial In Fosamax MDL
Merck & Co. Inc. suffered a blow during the last bellwether trial in multidistrict litigation alleging bone drug Fosamax causes jaw deterioration, as a New York federal jury ruled Tuesday that...To view the full article, register now.
Already a subscriber? Click here to view full article